References
- Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31 [PubMed: 11158037]
- Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762-9 [PubMed: 16846397]
- IMS National Prescription Audit. National Prescription Audit, June 2000–October 2009. Plymouth Meeting, PA: IMS Health Inc., 2010
- Asnani S, Cefalu CA, Naval-Srinivas RM. Testosterone replacement in the elderly: A clinical approach. Ann Long-Term Care 2003;11:44-50 [PubMed: n/a]
- Brawer MK. Testosterone replacement in men with andropause: an overview. Rev Urol 2004;6 (Suppl 6):S9-15 [PubMed: 16985914]
- Hayes FJ. Androgen replacement in the male: Recent studies. Curr Opin Endocrinol Diabetes 2001;8:301-6
- Oettel M. The endocrine pharmacology of testosterone therapy in men. Naturwissenschaften 2004;91:66-76 [PubMed: 14991143]
- Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92 [PubMed: 14749457]
- McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003;91:69-74 [PubMed: 12614254]
- Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-81 [PubMed: 12788872]
- Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-10 [PubMed: 11134099]
- Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-98 [PubMed: 15126525]
- Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 2001;54:739-50 [PubMed: 11422108]
- FortestaTM (testosterone) gel [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals Inc., 2010
- Rolf C, Knie U, Lemmitz G, et al. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 2002;56:637-41 [PubMed: 12030915]
- de Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009;24:425-8 [PubMed: 18948313]
- Brachet C, Vermeulen J, Heinrichs C. Children's virilization and the use of a testosterone gel by their fathers. Eur J Pediatr 2005;164:646-7 [PubMed: 16025298]
- Kunz GJ, Klein KO, Clemons RD, et al. Virilization of young children after topical androgen use by their parents. Pediatrics 2004;114:282-4 [PubMed: 15231947]
- Yu YM, Punyasavatsu N, Elder D, et al. Sexual development in a two-year-old boy induced by topical exposure to testosterone. Pediatrics 1999;104:e23 [PubMed: 10429141]
- Merhi ZO, Santoro N. Postmenopausal virilization after spousal use of topical androgens. Fertil Steril 2007;87:976.e13-15 [PubMed: 17254577]
- Bhowmick SK, Ricke T, Rettig KR. Sexual precocity in a 16-month-old-boy induced by indirect topical exposure to testosterone. Clin Pediatr (Phila) 2007;46:540-3 [PubMed: 17579107]
- Mazer N, Fisher D, Fischer J, et al. Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. J Sex Med 2005;2:227-34 [PubMed: 16422890]
- Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011;8:2079-89 [PubMed: 21492400]
- Miller J, Britto M, Fitzpatrick S, et al. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism. Endocr Pract 2011;17:574-83 [PubMed: 21454244]
- US Department of Health and Human Services (US Food and Drug Administration). Code of Federal Regulations - Title 21 - Food and Drugs. US Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm [Last accessed: 12 January 2012]
- Mayo Clinic Medical Laboratories. Clinical reference ranges for measurement of serum testosterone using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) methods. Rochester, MN: Mayo Foundation for Medical Education and Research. Available from: http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/8533 [Last accessed: 12 January 2012]
- Delanoe D, Fougeyrollas B, Meyer L, et al. Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1984;1:276 [PubMed: 6143012]
- Busse KL, Maibach HI. Transdermal estradiol and testosterone transfer in man: existence, models, and strategies for prevention. Skin Pharmacol Physiol 2011;24:57-66 [PubMed: 21088452]
- Testim® 1% (testosterone gel) [prescribing information]. Malvern, PA: Auxilium Pharmaceuticals, Inc., 2009
- Axiron® (testosterone) topical solution [prescribing information]. Indianapolis, IN: Lilly USA, LLC 2010
- Stahlman J, Britto M, Fitzpatrick S, et al. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Curr Med Res Opin 2012;28:291-301